glp-1 drugs pill form FDA approves new weight loss pill, offering more convenient option Novo's Wegovy Inches Closer to
Description
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: A randomised, controlled, double-blind, ascending dose and phase 2a study
p = 0.02) (Wiberg et al., 2018)
Psychoneuroendocrinology , 38(8), 12591270.
Results of these trials showed GLP-1 agonists have a favorable safety profile, with most side effects being mild and temporary
-1.3% and -1.6% with exenatide once-weekly)
